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Abstract: Actinic keratoses are areas of intraepithelial neoplasia for which treatment 
is necessary. Because they arise in areas of sun damage, it is desirable to treat the entire dam-
aged field to not only treat visible lesions, but also subclinical, emerging malignancies, ie, 
“field therapy”, 5-fluorouracil, imiquimod, and diclofenac are all treatment options, and are 
discussed and compared.
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Introduction
Actinic keratoses develop in fair-skinned individuals with a history of overexposure to 
ultraviolet light.1 Actinic keratosis is the third most common skin complaint treated by 
dermatologists in the US and, according to the American Academy of Dermatology, 
60% of predisposed individuals over the age of 40 years have at least one lesion.2,3 
They occur most frequently on sun-exposed skin of the face, scalp, arms, and hands. 
Important risk factors include fair skin, cumulative sun exposure, and immunosuppres-
sion, including further ultraviolet light exposure. Actinic keratosis is now considered 
to be the beginning of a biologic continuum that leads to invasive squamous cell 
carcinoma,1,4,5 thus treatment is medically necessary.
Pathology and epidemiology
Clinically, actinic keratoses present as erythematous keratotic macules, papules, and 
plaques. Most patients have multiple lesions, and will continue to develop new lesions 
from past ultraviolet-induced DNA damage, as well as cutaneous immunosuppres-
sion caused by continuing exposure. Histologically, an intraepithelial proliferation 
of abnormal keratinocytes is observed. When these atypical keratinocytes extend 
beyond the basement membrane, invasive squamous cell carcinoma is the result. 
Normal-appearing skin surrounding areas of actinic keratosis demonstrates molecu-
lar changes, including p53 gene mutations, and thus the whole area has the potential 
to develop more actinic keratoses and subsequently, squamous cell carcinoma.6 
Actinic keratosis and squamous cell carcinoma share epidemiologic, cytologic, and 
molecular features.1,7,8 Epidemiologic data indicate that up to 10% of actinic kera-
tosis lesions may progress to squamous cell carcinoma within 10 years, and 60% of 
squamous cell carcinomas arise from clinically diagnosed actinic keratoses.9 Because 
of the substantial risk of progression of actinic keratosis to squamous cell carcinoma 
and the inability to predict the behavior of individual lesions, current management Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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guidelines recommend considering treatment of all actinic 
keratoses.10–13 The presence of field cancerization suggests 
that proper long-term management of actinic keratoses will 
require repeated treatment of continuously evolving lesions.14 
Current treatments include in-office destructive therapy for 
individual actinic keratoses, such as cryosurgical destruction 
and photodynamic therapy. Patient-applied topical therapy 
offers treatment of a wider area affected by DNA damage 
and field cancerization. Actinic keratosis is a marker for an 
area that is at risk for development of more actinic keratoses 
and even squamous cell carcinoma; therefore, field treatment 
is recommended.13
Available topical therapies
The first field therapy to be approved was 5-fluorouracil, in 
1962. Rapidly growing cells need thiamine, and putting a 
fluorine atom in the 5-position on a uracil molecule simulates 
thiamine, but when metabolized by rapidly growing cells, 
kills them. The result is death of actinic keratosis cells. Recent 
preliminary data from Stockfleth et al13 show an increase in 
p53 tumor suppressor gene mutations in fields treated with 
5-fluorouracil (Pers comm; Stockfleth, 2011). In two studies, 
facial actinic keratoses treated with 5-fluorouracil twice daily 
for four weeks showed 100% clearance in 43% and 47.6% of 
patients after treatment.15,16 Sequelae of treatment with topical 
5-fluorouracil include erythema, crusting, oozing, burning, 
and pain, which may sometimes be severe.
Imiquimod 5% was first approved as a treatment for 
external genital warts in 1997. It is an immune response 
modifier and cytokine inducer. Imiquimod upregulates cell-
mediated immunity, which is effective against viruses and 
tumors, and has been approved for treating actinic keratoses 
and superficial basal cell carcinoma. Four weeks after treat-
ing facial actinic keratoses twice a week for 16 weeks, the 
100% clearance rate was 44%–46%.17 Recently, imiquimod 
3.75% was approved in the US for treating actinic keratosis 
of the face and scalp using a simplified daily dosing regimen 
(two weeks on, two weeks off, two weeks on) with similar 
efficacy to imiquimod 5% used twice a week for 16 weeks, 
and lower efficacy than imiquimod used three times weekly 
for 16 weeks.18 Side effects include skin irritation, which is 
dependent on dose and the immune status of the patient, and 
flu-like symptoms (fever, chills, aches, and pains). These 
sequelae are caused by increased levels of interferon, are 
more common with the 5% formulation, and increase with 
increased frequency of use and larger area of application.
Diclofenac is a nonsteroidal anti-inflammatory drug 
(NSAID). Its proposed mechanism of action in treating 
actinic keratoses is blocking cyclo-oxygenase-2 (COX-2), 
thereby reducing angiogenesis and cellular proliferation. 
Recently, topical diclofenac has been shown to upregulate 
apoptosis. Induction of apoptosis appears to be highly charac-
teristic of the mode of action of diclofenac in hyaluronic acid, 
and the therapeutic effect may be related to sensitization of 
neoplastic keratinocytes for death ligand-induced apoptosis.19 
Thus, it is believed that diclofenac starves out the dysplastic 
keratinocytes while causing programmed cell death, which 
results in lesion clearance with a minimum of inflammation. 
Diclofenac 3% + hyaluronic acid 2.5% (SolarazeTM) is used 
twice a day for up to 90 days. Four weeks after 60 days of 
treatment, 100% of actinic keratoses were cleared in 33% 
of patients and, after 90 days of treatment, the 100% clear-
ance rate was 50%.20 A recent study has demonstrated that 
180 days of therapy with diclofenac shows no significant 
improvement over 90 days.21 A one-year extension study was 
performed that showed a further decrease in target (original) 
actinic keratoses from 90% to 95% after a year, although the 
cumulative actinic keratosis count had increased slightly as 
a result of new actinic keratoses developing in areas of field 
cancerization.22 Figure 1 demonstrates the steady decrease 
in the number of actinic keratoses over 90 days of treatment, 
and the further decrease 30 days and one year after comple-
tion of the 90-day course. Topical diclofenac + hyaluronic 
acid has been shown to be a safe and effective for treatment 
of actinic keratosis on the mucosal lip, with a minimum of 
irritation. In most cases, this consists of mild crusting, while 
the actinic keratoses are resolving. Patient satisfaction with 
this treatment is rated to be high.23 Diclofenac has been shown 
to be safe and effective in organ transplant recipients. Ulrich 
et al followed a group of 24 organ transplant patients for two 
years. In the active treatment group, none developed invasive 
squamous cell carcinoma.24
Adverse events with topical diclofenac include applica-
tion site reactions, itching, erythema, dry skin, exfoliation, 
localized edema, paresthesia, and less frequently, photosensi-
tivity (Solaraze package insert). The cutaneous reactions have 
been investigated, and are often patch test-negative.25–27 These 
researchers postulate a subset of actinic keratosis and skin 
cancer patients that are highly or at least more susceptible to 
local reactions caused by COX-2 inhibitors and peroxisome 
proliferator-activated receptor agonists.28 They speculate 
that underlying molecular differences exist in these patients 
that make the skin more susceptible to COX-2 inhibitors. 
Although rare, both photocontact and allergic contact der-
matitis has been reported.29 In two patients who developed 
maculopapular eruptions 48 and 72 hours after initiation of Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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treatment with diclofenac + hyaluronic acid, prick and intra-
dermal tests were negative at 20 minutes, but 24 hours later 
an erythematous infiltrate had appeared at the intradermal 
test site.30 These researchers suggested intradermal and patch 
tests as an indicator to diagnose reactions of this type.
The question of systemic absorption of diclofenac + 
hyaluronic acid gel has been raised. A series of four cases 
of upper gastrointestinal bleeding were reported with topical 
VoltarenTM gel, a formulation of diclofenac made to penetrate 
deeper (two were using it for backache, which was ultimately 
found to be caused by peptic ulcer disease).31 Solaraze, on the 
other hand, is in a hyaluronic acid vehicle which is designed to 
keep the drug in the epidermis and superficial dermis in order 
to optimize it for treatment of actinic keratosis. Therefore, 
the two products are not bioequivalent.
In 60 patients with actinic keratoses enrolled in clinical tri-
als of Solaraze, mean serum diclofenac levels were #20 µL/L 
at the end of treatment.32 In patients with compromised skin 
(mainly atopic dermatitis and other dermatitic conditions), 
approximately 10% of the drug contained in a 2 g dose of the 
gel was absorbed systemically in both normal and compro-
mised epidermis after application four times a day over seven 
days to a 100 cm2 area.32 Similarly, the drug was detected in 
the serum of healthy volunteers after applying the gel to the 
calf at a dosage of 2 g three times a day for six days.32 Mean 
peak plasma concentration, area under the curve (AUC), and 
time to peak plasma concentration were 4 µg/L, 9 µg/L · h/L, 
and 4.5 hours, respectively, after topical application. It should 
be noted that the recommended dose of Solaraze is twice 
daily, not three or four times daily. In contrast, an AUC of 
1600 µg · h/L was obtained after administration of a single 
75 mg oral dose of diclofenac, confirming that the systemic 
bioavailability of the drug is considerably lower after topical 
application of diclofenac + hyaluronic acid gel than systemic 
administration of diclofenac.32 More absorption studies need 
to be done on patients using diclofenac + hyaluronic acid at 
the recommended doses in actual clinical settings.
Topical diclofenac alone and concomitant use of sun-
screens has been shown not to induce photosensitivity or 
phototoxicity,33 but because such events have been reported, 
patients should be cautioned to avoid sun exposure.
Future development of topical 
treatment
Several promising new topicals are in various stages of 
development. Ingenol mebutate gel (formerly PEP005) is a 
diterpene ester extracted and purified from the Euphorbia 
peplus plant. It is being evaluated for the treatment of actinic 
keratosis. Phase II studies have suggested that a 0.05% 
concentration is optimal for sites other than the face and 
scalp, and lower concentrations are needed for sites on the 
head.34–38 Treatment is once daily for two or three consecutive 
days, and clearance rates are higher for higher concentra-
tions and three-day dosing. Optimal regimens have yet to be 
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Figure 1 Reduction in actinic keratosis (AK) lesions over time.22
Nelson C, Rigel D; Long term Follow-up of Diclofenac Sodium 3% in 2% Hyaluronic Acid Gel for Actinic Keratoses: One-Year evaluation. J Clin Aesthet Dermatol. 
2009;2(7):20–25. Copyright © 2009 Matrix Medical Communications. All rights reserved.
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determined. Side effects include erythema, scaling, scabbing, 
itching, and burning, and are dose-related. Other novel topical 
treatments under investigation include sulindac + hydrogen 
peroxide, oleogel-S-10, and nicotinic acid.
Discussion
Clearance rates for all of the available topical field treatments 
for actinic keratosis are comparable. A bilateral comparison 
(“split face”) study was conducted to assess the efficacy and 
tolerability of Solaraze twice daily for 90 days compared with 
5-fluorouracil 5% twice daily for 28 days in 30 patients with 
actinic keratoses of the face and scalp. The diclofenac gel 
and 5-fluorouracil cream each demonstrated substantial and 
comparable efficacy in the number of lesions cleared and the 
number of patients with significant clearing. In fact, there 
was no statistically significant difference between the two 
products. Diclofenac induced only mild signs of inflamma-
tion compared with 5-flurouracil, despite a longer treatment 
period. A greater number of patients expressed satisfaction 
with diclofenac + hyaluronic acid gel compared with the 
5-fluorouracil cream.39
Imiquimod is supplied in sachets, so much smaller quan-
tities are available, and clearance rates are much lower and 
the incidence of adverse events higher for nonfacial sites.40 
Solaraze is supplied in a 100 g tube, which makes it ideal for 
use on larger areas of skin, and for completion of the 90-day 
course of treatment. Compliance can be increased by explain-
ing to the patient that this medication works by “starving out” 
the actinic keratoses, so it requires longer to work, but the 
trade-off is that they will have much less irritation.
A cost effectiveness model was developed for the Italian 
health care system, in which diclofenac + hyaluronic acid, 
imiquimod 5%, and methylaminolevulanate + photody-
namic therapy were compared. 5-Fluorouracil is not avail-
able in Italy.41 Based on this cost-effectiveness model, 3% 
diclofenac + hyaluronic acid is considered the treatment of 
choice in the Italian health care system.
Solaraze has also proven effective in combination therapy 
regimens. In a large multicenter study of 521 patients, topical 
diclofenac + hyaluronic acid was used following cryosurgery, 
and significantly improved the clearance rate, ie, 100% clear-
ance of target plus cumulative lesions in 46% of patients, as 
opposed to 21% with cryosurgery alone.41
Conclusion
In 1985, John Knox proposed the four “Cs” for the treatment 
of basal cell carcinoma, and with today’s increased number 
of options, these apply to actinic keratosis treatment as well, 
ie, convenience, cost-effectiveness, cure rate, and cosmetic 
result. Moreover, a fifth “C” can now be added, ie, compli-
ance. Given the favorable safety profile and low rate of 
irritation with diclofenac, patients are more likely not only 
to complete their course of therapy, but be willing to use it 
again when necessary. Solaraze should be considered first-
line for field therapy of actinic keratosis.
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